Skip To Main Content
S.N. Lo on Muck Rack

S.N. Lo

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to S.N. Lo’s profile

Articles by S.N. Lo

Targeting the neonatal Fc receptor in pemphigus: safety first

|
By S.N. Lo, N. Rajan, G. Micevic
| Wiley Online Library Verified
Commentary G. Micevic, Corresponding Author G.
Open in Who Shared Issue with article?

MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies

|
By L.M. Hollestein, S.N. Lo, J. Leonardi-Bee, S. Rosset
| Wiley Online Library Verified
L.M. Hollestein, Corresponding Author L.M. Hollestein l.hollestein@erasmusmc.nl orcid.org/0000-0001-8922-6791 Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands Contribution: Writing - original draft (lead), Writing - review & editing (lead) Search for more papers by this author S.N. Lo, S.N. Lo orcid.org/0000-0001-5092-5544 Melanoma Institute...
Open in Who Shared Issue with article?

Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!

|
By S.N. Lo, J.F. Thompson
| Wiley Online Library Verified
Commentary S.N. Lo, Corresponding Author serigne.lo@melanoma.org.au orcid.org/0000-0001-5092-5544 Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Contribution: Conceptualization (equal), Formal analysis (equal), Writing - original draft (equal), Writing - review & editing (equal) Search for more papers by this author J.F. Thompson, orcid.org/0000-0002-2816-2496 Melanoma Institute...
Open in Who Shared Issue with article?

FDG-PET to predict long-term outcome from anti-PD1 therapy in metastatic melanoma

|
By L. Emmett, F. Dimitriou, S.N. Lo, A.C. Tan
| annalsofoncology.org
Highlights • FDG-PET has been shown to predict short-term outcomes with anti-PD1 therapy better than CT • At 5-years, patients with complete metabolic response (CMR) on 1-year PET had sustained responses (PFS 90%) • This was greater in those with complete response (PFS 93%), as most patients with partial response have CMR (PFS 88%) • In the minority that progress, often in solitary sites and managed locally, overall survival remains excellent • PET may have utility in predicting long-term...
Open in Who Shared Issue with article?
Show More